Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.355 USD | -3.09% | +5.63% | -0.21% |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
May. 30 | Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise | MT |
Financials (USD)
Sales 2024 * | 185M | Sales 2025 * | 219M | Capitalization | 360M |
---|---|---|---|---|---|
Net income 2024 * | -60M | Net income 2025 * | -30M | EV / Sales 2024 * | 1.95 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.64 x |
P/E ratio 2024 * |
-5.76
x | P/E ratio 2025 * |
-11.6
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.09% |
Latest transcript on Xeris Biopharma Holdings, Inc.
1 day | +4.97% | ||
1 week | +25.91% | ||
Current month | +7.76% | ||
1 month | +28.57% | ||
3 months | -21.10% | ||
6 months | +30.65% | ||
Current year | +3.40% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Edick
CEO | Chief Executive Officer | 67 | 21-04-30 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 21-09-30 |
John Shannon
PSD | President | 62 | 21-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +10.33% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 2.345 | -3.50% | 463 422 |
24-06-05 | 2.43 | +4.74% | 1,747,746 |
24-06-04 | 2.32 | -5.31% | 1,849,224 |
24-06-03 | 2.45 | +8.65% | 3,771,081 |
24-05-31 | 2.255 | +1.58% | 2,923,991 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.40% | 360M | |
+42.69% | 749B | |
+38.96% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+18.92% | 248B | |
-2.41% | 214B | |
+11.30% | 216B | |
+2.64% | 167B |
- Stock Market
- Equities
- XERS Stock